Key Points
- Genelux director John Thomas sold 10,000 shares on June 1 at an average price of $2.98, totaling $29,800. The sale was made under a pre-arranged Rule 10b5-1 plan, and he still owns 472,784 shares.
- GNLX shares were down 0.7% and traded around $2.95, leaving the company with a market cap of about $132 million. The stock remains well below its 52-week high of $8.53 and slightly above its 52-week low of $2.29.
- Genelux recently reported a loss of $0.20 per share, missing analyst expectations, and analysts currently have a Moderate Buy consensus with an average price target of $18.00. Institutional investors own about 37.33% of the company.
Genelux Corporation (NASDAQ:GNLX - Get Free Report) Director John Thomas sold 10,000 shares of the firm's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $2.98, for a total transaction of $29,800.00. Following the transaction, the director owned 472,784 shares in the company, valued at $1,408,896.32. This represents a 2.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Genelux Trading Down 0.7%
Genelux stock opened at $2.95 on Wednesday. The company has a market capitalization of $132.28 million, a P/E ratio of -3.47 and a beta of 0.56. The firm's fifty day simple moving average is $2.73 and its 200-day simple moving average is $3.26. Genelux Corporation has a 1-year low of $2.29 and a 1-year high of $8.53.
Genelux (NASDAQ:GNLX - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). On average, equities research analysts predict that Genelux Corporation will post -0.8 earnings per share for the current year.
Analyst Ratings Changes
A number of research analysts have recently weighed in on GNLX shares. Wall Street Zen downgraded shares of Genelux from a "hold" rating to a "sell" rating in a report on Saturday, April 11th. Weiss Ratings restated a "sell (e+)" rating on shares of Genelux in a report on Tuesday, April 21st. Finally, Benchmark cut their price target on shares of Genelux from $23.00 to $20.00 and set a "speculative buy" rating on the stock in a report on Friday, March 20th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Genelux has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
Get Our Latest Stock Report on Genelux
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of GNLX. Jefferies Financial Group Inc. bought a new position in Genelux in the 4th quarter worth $48,000. Squarepoint Ops LLC bought a new position in Genelux in the 4th quarter worth $52,000. Raymond James Financial Inc. raised its holdings in Genelux by 22.6% in the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company's stock worth $83,000 after acquiring an additional 5,333 shares during the period. Marshall Wace LLP bought a new position in Genelux in the 2nd quarter worth $92,000. Finally, Balyasny Asset Management L.P. bought a new position in Genelux in the 4th quarter worth $94,000. Institutional investors own 37.33% of the company's stock.
Genelux Company Profile
(
Get Free Report)
Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company's programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux's lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.
Genelux's pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
